Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Early Diagnosis of Pathogen Infection by Cell-Based Activation Immunoassay.

Bar-Haim E, Rotem S, Elia U, Bercovich-Kinori A, Israeli M, Cohen-Gihon I, Israeli O, Erez N, Achdout H, Zauberman A, Aftalion M, Mamroud E, Chitlaru T, Cohen O.

Cells. 2019 Aug 22;8(9). pii: E952. doi: 10.3390/cells8090952.

2.

Disruption of the NlpD lipoprotein of the plague pathogen Yersinia pestis affects iron acquisition and the activity of the twin-arginine translocation system.

Tidhar A, Levy Y, Zauberman A, Vagima Y, Gur D, Aftalion M, Israeli O, Chitlaru T, Ariel N, Flashner Y, Zvi A, Mamroud E.

PLoS Negl Trop Dis. 2019 Jun 6;13(6):e0007449. doi: 10.1371/journal.pntd.0007449. eCollection 2019 Jun.

3.

Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.

Zauberman A, Gur D, Levy Y, Aftalion M, Vagima Y, Tidhar A, Chitlaru T, Mamroud E.

J Infect Dis. 2019 Aug 30;220(7):1147-1151. doi: 10.1093/infdis/jiz260.

PMID:
31095689
4.

Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague.

Levy Y, Vagima Y, Tidhar A, Aftalion M, Gur D, Nili U, Chitlaru T, Zauberman A, Mamroud E.

NPJ Vaccines. 2018 Oct 19;3:52. doi: 10.1038/s41541-018-0087-z. eCollection 2018.

5.

Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model.

Gur D, Glinert I, Aftalion M, Vagima Y, Levy Y, Rotem S, Zauberman A, Tidhar A, Tal A, Maoz S, Ber R, Pass A, Mamroud E.

Front Microbiol. 2018 Apr 24;9:741. doi: 10.3389/fmicb.2018.00741. eCollection 2018.

6.

Host Iron Nutritional Immunity Induced by a Live Yersinia pestis Vaccine Strain Is Associated with Immediate Protection against Plague.

Zauberman A, Vagima Y, Tidhar A, Aftalion M, Gur D, Rotem S, Chitlaru T, Levy Y, Mamroud E.

Front Cell Infect Microbiol. 2017 Jun 21;7:277. doi: 10.3389/fcimb.2017.00277. eCollection 2017.

7.

Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.

Zvi A, Rotem S, Zauberman A, Elia U, Aftalion M, Bar-Haim E, Mamroud E, Cohen O.

Vaccine. 2017 Oct 20;35(44):5995-6006. doi: 10.1016/j.vaccine.2017.05.092. Epub 2017 Jun 9.

PMID:
28606812
8.

Adjunctive Corticosteroid Treatment Against Yersinia pestis Improves Bacterial Clearance, Immunopathology, and Survival in the Mouse Model of Bubonic Plague.

Levy Y, Vagima Y, Tidhar A, Zauberman A, Aftalion M, Gur D, Fogel I, Chitlaru T, Flashner Y, Mamroud E.

J Infect Dis. 2016 Sep 15;214(6):970-7. doi: 10.1093/infdis/jiw290. Epub 2016 Jul 11.

PMID:
27402776
9.

M-sec regulates polarized secretion of inflammatory endothelial chemokines and facilitates CCL2-mediated lymphocyte transendothelial migration.

Barzilai S, Blecher-Gonen R, Barnett-Itzhaki Z, Zauberman A, Lebel-Haziv Y, Amit I, Alon R.

J Leukoc Biol. 2016 Jun;99(6):1045-55. doi: 10.1189/jlb.3VMA0915-427R. Epub 2015 Dec 23.

PMID:
26701136
10.

Circumventing Y. pestis Virulence by Early Recruitment of Neutrophils to the Lungs during Pneumonic Plague.

Vagima Y, Zauberman A, Levy Y, Gur D, Tidhar A, Aftalion M, Shafferman A, Mamroud E.

PLoS Pathog. 2015 May 14;11(5):e1004893. doi: 10.1371/journal.ppat.1004893. eCollection 2015 May.

11.

Transendothelial migration of effector T cells across inflamed endothelial barriers does not require heparan sulfate proteoglycans.

Stoler-Barak L, Barzilai S, Zauberman A, Alon R.

Int Immunol. 2014 Jun;26(6):315-24. doi: 10.1093/intimm/dxt076. Epub 2014 Jan 8.

PMID:
24402310
12.

YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].

Zauberman A, Flashner Y, Levy Y, Vagima Y, Tidhar A, Cohen O, Bar-Haim E, Gur D, Aftalion M, Halperin G, Shafferman A, Mamroud E.

PLoS One. 2013 Dec 16;8(12):e83560. doi: 10.1371/journal.pone.0083560. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/0ec1f217-4e7a-4dee-9a71-1076a3ac73f1.

13.

Novel membrane-bound reporter molecule for sorting high producer cells by flow cytometry.

Helman D, Toister-Achituv M, Bar-Shimon M, Cohen B, Otmi I, Berger N, Kalimi D, Kimalov B, Medina T, Sapir A, Rotemberg O, Zabavnik N, Zauberman A, Smolarsky M.

Cytometry A. 2014 Feb;85(2):162-8. doi: 10.1002/cyto.a.22308. Epub 2013 Jun 13.

14.

Early sensing of Yersinia pestis airway infection by bone marrow cells.

Vagima Y, Levy Y, Gur D, Tidhar A, Aftalion M, Abramovich H, Zahavy E, Zauberman A, Flashner Y, Shafferman A, Mamroud E.

Front Cell Infect Microbiol. 2012 Nov 26;2:143. doi: 10.3389/fcimb.2012.00143. eCollection 2012.

15.

T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.

Levy Y, Flashner Y, Tidhar A, Zauberman A, Aftalion M, Lazar S, Gur D, Shafferman A, Mamroud E.

Vaccine. 2011 Sep 16;29(40):6866-73. doi: 10.1016/j.vaccine.2011.07.059. Epub 2011 Jul 29.

PMID:
21803090
16.

Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.

Pini A, Shemesh R, Samuel CS, Bathgate RA, Zauberman A, Hermesh C, Wool A, Bani D, Rotman G.

J Pharmacol Exp Ther. 2010 Dec;335(3):589-99. doi: 10.1124/jpet.110.170977. Epub 2010 Sep 8.

PMID:
20826567
17.

The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague.

Tidhar A, Flashner Y, Cohen S, Levi Y, Zauberman A, Gur D, Aftalion M, Elhanany E, Zvi A, Shafferman A, Mamroud E.

PLoS One. 2009 Sep 14;4(9):e7023. doi: 10.1371/journal.pone.0007023.

18.

Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague.

Zauberman A, Tidhar A, Levy Y, Bar-Haim E, Halperin G, Flashner Y, Cohen S, Shafferman A, Mamroud E.

PLoS One. 2009 Jun 16;4(6):e5938. doi: 10.1371/journal.pone.0005938.

19.

A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects.

Hecht I, Rong J, Sampaio AL, Hermesh C, Rutledge C, Shemesh R, Toporik A, Beiman M, Dassa L, Niv H, Cojocaru G, Zauberman A, Rotman G, Perretti M, Vinten-Johansen J, Cohen Y.

J Pharmacol Exp Ther. 2009 Feb;328(2):426-34. doi: 10.1124/jpet.108.145821. Epub 2008 Nov 20.

PMID:
19023040
20.

Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.

Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.

Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6.

PMID:
18304706
21.

Disparity between Yersinia pestis and Yersinia enterocolitica O:8 in YopJ/YopP-dependent functions.

Zauberman A, Velan B, Mamroud E, Flashner Y, Shafferman A, Cohen S.

Adv Exp Med Biol. 2007;603:312-20.

PMID:
17966427
22.

Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity.

Galun E, Terrault NA, Eren R, Zauberman A, Nussbaum O, Terkieltaub D, Zohar M, Buchnik R, Ackerman Z, Safadi R, Ashur Y, Misrachi S, Liberman Y, Rivkin L, Dagan S.

J Hepatol. 2007 Jan;46(1):37-44. Epub 2006 Oct 20.

PMID:
17112624
23.

Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration.

Velan B, Bar-Haim E, Zauberman A, Mamroud E, Shafferman A, Cohen S.

Infect Immun. 2006 Nov;74(11):6365-76. Epub 2006 Aug 21.

24.

Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis.

Zauberman A, Cohen S, Mamroud E, Flashner Y, Tidhar A, Ber R, Elhanany E, Shafferman A, Velan B.

Infect Immun. 2006 Jun;74(6):3239-50.

25.

The use of the hydrodynamic HBV animal model to study HBV biology and anti-viral therapy.

Ketzinel-Gilad M, Zauberman A, Nussbaum O, Shoshany Y, Ben-Moshe O, Pappo O, Felig Y, Ilan E, Wald H, Dagan S, Galun E.

Hepatol Res. 2006 Apr;34(4):228-37. Epub 2006 Mar 7.

PMID:
16520091
26.

Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.

Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z, Aviel S, Ilan E, Shoshany Y, Neville L, Waisman T, Ben-Moshe O, Kischitsky A, Foung SK, Keck ZY, Pappo O, Eid A, Jurim O, Zamir G, Galun E, Dagan S.

J Virol. 2006 Mar;80(6):2654-64.

27.

Oligonucleotide-assisted cleavage and ligation: a novel directional DNA cloning technology to capture cDNAs. Application in the construction of a human immune antibody phage-display library.

Schoonbroodt S, Frans N, DeSouza M, Eren R, Priel S, Brosh N, Ben-Porath J, Zauberman A, Ilan E, Dagan S, Cohen EH, Hoogenboom HR, Ladner RC, Hoet RM.

Nucleic Acids Res. 2005 May 19;33(9):e81.

28.

The Trimera mouse: a system for generating human monoclonal antibodies and modeling human diseases.

Ilan E, Eren R, Lubin I, Nussbaum O, Zauberman A, Dagan S.

Curr Opin Mol Ther. 2002 Apr;4(2):102-9. Review.

PMID:
12044030
29.

The mesenchyme expresses T cell receptor mRNAs: relevance to cell growth control.

Barda-Saad M, Shav-Tal Y, Rozenszajn AL, Cohen M, Zauberman A, Karmazyn A, Parameswaran R, Schori H, Ashush H, Ben-Nun A, Zipori D.

Oncogene. 2002 Mar 27;21(13):2029-36.

30.

The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV.

Ilan E, Arazi J, Nussbaum O, Zauberman A, Eren R, Lubin I, Neville L, Ben-Moshe O, Kischitzky A, Litchi A, Margalit I, Gopher J, Mounir S, Cai W, Daudi N, Eid A, Jurim O, Czerniak A, Galun E, Dagan S.

J Infect Dis. 2002 Jan 15;185(2):153-61. Epub 2002 Jan 3.

PMID:
11807688
31.
32.

Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees.

Eren R, Ilan E, Nussbaum O, Lubin I, Terkieltaub D, Arazi Y, Ben-Moshe O, Kitchinzky A, Berr S, Gopher J, Zauberman A, Galun E, Shouval D, Daudi N, Eid A, Jurim O, Magnius LO, Hammas B, Reisner Y, Dagan S.

Hepatology. 2000 Sep;32(3):588-96.

PMID:
10960454
33.

Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3.

Zauberman A, Zipori D, Krupsky M, Ben-Levy R.

Oncogene. 1999 Jul 1;18(26):3886-93.

35.

Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system.

Eren R, Lubin I, Terkieltaub D, Ben-Moshe O, Zauberman A, Uhlmann R, Tzahor T, Moss S, Ilan E, Shouval D, Galun E, Daudi N, Marcus H, Reisner Y, Dagan S.

Immunology. 1998 Feb;93(2):154-61.

36.

p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53.

Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y.

EMBO J. 1998 Jan 15;17(2):544-53.

37.
38.

A functional p53-responsive intronic promoter is contained within the human mdm2 gene.

Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M.

Nucleic Acids Res. 1995 Jul 25;23(14):2584-92.

39.
40.

Targets for transcriptional activation by wild-type p53: endogenous retroviral LTR, immunoglobulin-like promoter, and an internal promoter of the mdm2 gene.

Barak Y, Lupo A, Zauberman A, Juven T, Aloni-Grinstein R, Gottlieb E, Rotter V, Oren M.

Cold Spring Harb Symp Quant Biol. 1994;59:225-35. No abstract available.

PMID:
7587074
41.

Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.

Juven T, Barak Y, Zauberman A, George DL, Oren M.

Oncogene. 1993 Dec;8(12):3411-6.

PMID:
8247544
42.
43.
44.
45.

Cotransfection of granulosa cells with simian virus 40 and Ha-RAS oncogene generates stable lines capable of induced steroidogenesis.

Amsterdam A, Zauberman A, Meir G, Pinhasi-Kimhi O, Suh BS, Oren M.

Proc Natl Acad Sci U S A. 1988 Oct;85(20):7582-6.

Supplemental Content

Loading ...
Support Center